Loading
A phase 2 trial of Contrast-enhanced mammography in Breast cancer, run by European Institute of Oncology, with a status the registry has not verified recently.
Contrast-Enhanced Spectral Mammography (CESM) is a phase 2 interventional study registered as NCT06311695 by European Institute of Oncology, with 263 participants planned, started 2020-11-16 and due to reach its primary completion in 2025-02-28. Interventions recorded: Contrast Enhanced Mammography. Conditions recorded: Breast Cancer.
Linked to the technology Contrast-enhanced mammography because the registry names it ("contrast enhanced mammography") among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.